NextCure (NXTC) to Release Earnings on Monday

NextCure (NASDAQ:NXTC) is expected to be posting its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to post earnings of ($1.95) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. On average, analysts expect NextCure to post $-8 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

NextCure Trading Down 17.7%

NASDAQ:NXTC opened at $4.14 on Friday. The stock has a market capitalization of $14.95 million, a PE ratio of -0.24 and a beta of 1.42. NextCure has a 1-year low of $1.55 and a 1-year high of $15.74. The firm has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $8.68.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NXTC. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of NextCure in a research note on Wednesday, July 15th. Finally, Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, NextCure has a consensus rating of “Hold” and an average target price of $19.00.

Insider Transactions at NextCure

In other news, major shareholder Adar1 Capital Management, Llc acquired 6,400 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were purchased at an average cost of $4.95 per share, with a total value of $31,680.00. Following the acquisition, the insider directly owned 389,856 shares in the company, valued at $1,929,787.20. This represents a 1.67% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders acquired 17,608 shares of company stock valued at $87,720. Insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On NextCure

Institutional investors have recently modified their holdings of the business. Cable Car Capital LP lifted its position in shares of NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the period. Geode Capital Management LLC increased its position in shares of NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC raised its stake in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares in the last quarter. Exome Asset Management LLC acquired a new position in NextCure in the fourth quarter valued at about $2,341,000. Finally, AWM Investment Company Inc. acquired a new position in NextCure in the fourth quarter valued at about $1,665,000. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.